Indications
Alzheimer’s type dementia, vascular dementia, mixed dementia of all degrees of severity.
$536.00
Active ingredient: | |
---|---|
Dosage form: | |
Indications for use: | Alcoholism, Alzheimer's disease, Concussion and other brain injuries, Consequences of a stroke, Dementia |
Alzheimer’s type dementia, vascular dementia, mixed dementia of all degrees of severity.
Acatinol Memantine is taken orally, with meals. The dosage regimen is set individually. It is recommended to start treatment with the minimum effective dose.
Adults with dementia during the 1st week of therapy — at a dose of 5 mg / day, the 2nd week-at a dose of 10 mg/day, the 3rd week-at a dose of 15-20 mg/day. If necessary, a further weekly dose increase of 10 mg is possible until the daily dose of 30 mg is reached.
The optimal dose is achieved gradually, with an increase in the dose every week.
With caution:
Active ingredient:
memantine gilrochloride 20 mg;
Excipients:
lactose,
MCC,
colloidal silicon dioxide,
talc,
magnesium stearate,
Shell:
methacrylic acid copolymer,
sodium lauryl sulfate,
talc.
Active ingredient:
memantine gilrochloride 20 mg;
Auxiliary substances:
lactose,
MCC,
colloidal silicon dioxide,
talc,
magnesium stearate,
Shell:
methacrylic acid copolymer,
sodium lauryl sulfate,
talc.
Pharmacodynamics
Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system. Regulates ion transport, blocks calcium channels, normalizes the membrane potential, and improves the process of nerve impulse transmission. Improves cognitive processes, increases daily activity.
Pharmacokinetics
After oral use, Acatinol Memantine is rapidly and completely absorbed. The maximum concentration in the blood plasma is reached within 2-6 hours. No accumulation of the drug was observed in normal renal function. Elimination proceeds in two phases. The elimination half-life is 4-9 hours in the first phase and 40-65 hours in the second phase. It is excreted in the urine.
Alzheimer’s type dementia, vascular dementia, mixed dementia of all degrees of severity.
With caution:
Adverse reactions are classified according to clinical manifestations (according to the lesion of certain organ systems) and frequency of occurrence:
On the part of the body as a whole — common adverse reactions | Often | Headache |
Rarely | Fatigue | |
Infections | Rarely | Fungal infections |
Mental disorders | Are Common | Drowsiness |
Rarely | Confusion of consciousness | |
Rare | Hallucinations 1 | |
Frequency not established | Psychotic reactions 2 | |
Disorders of the cardiovascular system | Rarely | Hypertension |
Rarely | Venous thrombosis / thromboembolism | |
Gastrointestinal disorders | Often | Constipation |
Rarely | Nausea, vomiting | |
Frequency not established | Pancreatitis 2 | |
Central and peripheral nervous system disorders | are common | Vertigo |
Rarely | Gait disorder | |
Very rare | Seizures |
and Hallucinations were observed mainly in patients with Alzheimer’s disease at the stage of severe dementia.
2 There are isolated reports of these adverse reactions occurring with the use of the drug in clinical practice (data obtained after the drug became commercially available).
When used concomitantly with barbiturates, neuroleptics, anticholinergics, the effect of the latter may increase. When used together, it can change (increase or decrease) the effect of dantrolene or baclofen, so the dosage of drugs should be selected individually.
Acatinol Memantine is taken orally, with meals. The dosage regimen is set individually. It is recommended to start treatment with the minimum effective dose.
Adults with dementia during the 1st week of therapy — at a dose of 5 mg / day, the 2nd week-at a dose of 10 mg/day, the 3rd week-at a dose of 15-20 mg/day. If necessary, a further weekly dose increase of 10 mg is possible until the daily dose of 30 mg is reached.
The optimal dose is achieved gradually, with an increase in the dose every week.
Symptoms: Â increased severity of side effects.
Treatment: Â gastric lavage, taking activated charcoal, symptomatic therapy.
The optimal dose is achieved gradually, with an increase in the dose every week.
Film-coated tablets
At a temperature not exceeding 25 °C
4 years
Memantine
By prescription
Tablets
For adults as directed by your doctor
Acquired Dementia, Alzheimer’s disease, Alcoholism, Stroke effects, Concussion and other traumatic brain injuries
Reviews
There are no reviews yet